2015 Publication

Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology. World J Clin Oncol. 2015 Dec 10;6(6):184-8. doi: 10.5306/wjco.v6.i6.184.
Reinhold WC.

Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. Clin Cancer Res. 2015 Jun 5. pii: clincanres.0335.2015. [Epub ahead of print].
Reinhold WC, Sunshine M, Varma S, Doroshow JH, Pommier Y.

Bisphosphonates as new anticancer agents? Bull Cancer. 2015 Apr;102(4):297-9.
Robert J, Reinhold WC.

The 15kDa selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways. PLoS One. 2015 Apr 17;10(4):e0124487.
Tsuji PA, Carlson BA, Yoo MH, Naranjo-Suarez S, Xu XM, He Y, Asaki E, Seifried HE, Reinhold WC, Davis CD, Gladyshev VN, Hatfield DL.

Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. DNA Repair. 2015 Feb 11. pii: S1568-7864(15)00023-3.
Sousa FG, Matuo R, Tang SW, Rajapakse VN, Luna A, Sander C, Varma S, Simon PH, Doroshow JH, Reinhold WC, Pommier Y.

Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer. Hum Genet. 2015 Jan;134(1):3-11. doi: 10.1007/s00439-014-1482-9. Epub 2014 Sep 12.
Reinhold WC, Varma S, Rajapakse VN, Luna A, Sousa FG, Kohn KW, Pommier YG.